2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Snyder, J. J. Articles by Collins, A. J. Search for Related Content PubMed PubMed Citation Articles by Snyder, J. J. Articles by Collins, A. J.

Hemoglobin Levels and Erythropoietin Doses in Hemodialysis and Peritoneal Dialysis Patients in the United States

Jon J. Snyder^*, Robert N. Foley^*, David T. Gilbertson^*, Edward F. Vonesh and Allan J. Collins^*

*Nephrology Analytical Services, Minneapolis Medical Research Foundation, Minneapolis, Minnesota; and Applied Statistics Center, Baxter Healthcare Corporation, Round Lake, Illinois

Correspondence to Robert N. Foley, Nephrology Analytical Services, 914 South 8th Street, Suite D-206, Minneapolis, MN 55404. Phone: 612-337-5979; Fax: 612-347-7781;

ABSTRACT. Erythropoietic agents, a cornerstone of management, are a major component of the cost of renal replacement therapy. The objectives of this study were to compare (on a month-by-month basis) U.S. hemodialysis and peritoneal dialysis patients in terms of the proportion of patients receiving erythropoietin, erythropoietin doses, and hemoglobin levels after initiation of erythropoietin. Patients studied (hemodialysis, n = 121,970; peritoneal dialysis, n = 7129) began dialysis between 1995 and 2000, had Medicare as their primary payer, were 65 yr old or older at dialysis inception, had no erythropoietin claims before dialysis inception, and did not have a switch in dialysis modality in the first 6 mo of dialysis therapy. Total monthly erythropoietin doses and average monthly hemoglobin levels were calculated from Medicare claims. The proportion of patients who received erythropoietin plateaued at 3 mo in both groups: 25% in peritoneal dialysis patients and 80% in hemodialysis patients. However, monthly erythropoietin doses plateaued at 30,000 units in peritoneal dialysis patients and 60,000 units in hemodialysis patients, a disparity not explicable by differences in baseline characteristics. Among subjects who received erythropoietin, mean hemoglobin levels were similar at steady state in both populations and met the National Kidney Foundation Dialysis Outcomes Quality Initiative hemoglobin target level of 11 to 12 g/dl. Hemoglobin levels in U.S. hemodialysis and peritoneal populations are similar. However, erythropoietin doses are dramatically higher in hemodialysis patients. E-mail: RFoley@nephrology.org

This article has been cited by other articles:

				B. S. Spinowitz Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin {delta} Haematologica, May 1, 2008; 93(5): 761 - 764. [Abstract] [Full Text] [PDF]

				L. Segall and A. Covic Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis Nephrol. Dial. Transplant., January 1, 2007; 22(1): 59 - 63. [Full Text] [PDF]

				S. Al-Khoury, N. Shah, B. Afzali, A. Covic, J. Taylor, and D. Goldsmith Post-transplantation anaemia in adult and paediatric renal allograft recipients--Guy's Hospital experience Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1974 - 1980. [Abstract] [Full Text] [PDF]

				J. K. Inrig, J. L. Sun, Q. Yang, L. P. Briley, and L. A. Szczech Mortality by Dialysis Modality among Patients Who Have End-Stage Renal Disease and Are Awaiting Renal Transplantation Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 774 - 779. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673